share_log

A Quick Look at Today's Ratings for Elevance Health(ELV.US), With a Forecast Between $520 to $625

Futu News ·  Oct 18 21:00  · Ratings

On Oct 18, major Wall Street analysts update their ratings for $Elevance Health (ELV.US)$, with price targets ranging from $520 to $625.

Barclays analyst Andrew Mok CFA maintains with a buy rating, and maintains the target price at $622.

UBS analyst A.J. Rice maintains with a buy rating, and adjusts the target price from $605 to $555.

Wells Fargo analyst Steve Baxter maintains with a buy rating, and maintains the target price at $593.

Mizuho Securities analyst Ann Hynes maintains with a buy rating.

Baird analyst Michael Ha maintains with a buy rating, and maintains the target price at $625.

Furthermore, according to the comprehensive report, the opinions of $Elevance Health (ELV.US)$'s main analysts recently are as follows:

  • The firm notes that despite the positive trends observed in the company's commercial and Carelon units, pressures from the Medicaid segment are overshadowing these developments following the Q3 report.

Here are the latest investment ratings and price targets for $Elevance Health (ELV.US)$ from 7 analysts:

StockTodayLatestRating_nn_82334523291606_20241018_en

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment